Formulari Ubat KKM (FUKKM)

# Generic Name MDC Category Indications Pres. Restrictions Dosage
391 Clozapine 100 mg Tablet N05AH02000T1002XX A Treatment of resistant schizophrenia Initial dose : 12.5 mg ( once or twice ) daily, increase slowly in steps of 25 - 50 mg up to 300 mg daily within 2 - 3 weeks. Maximum 900 mg/day
392 Clozapine 25 mg Tablet N05AH02000T1001XX A Treatment of resistant schizophrenia Initial dose : 12.5 mg ( once or twice ) daily, increase slowly in steps of 25 - 50 mg up to 300 mg daily within 2 - 3 weeks. Maximum 900 mg/day
393 Coal Tar 20% Solution D05AA00-000-L52-01-XXX B Dandruff, seborrhoeic dermatitis, atopic dermatitis, eczema and psoriasis. None To dilute 1 cap (15 ml) into 10L of water and soak for 20 minutes.
394 Coal Tar and Salicylic Acid (various concentrations) Ointment D05AA00-946-G50-02-XXX B Dandruff, seborrhoeic dermatitis, atopic dermatitis, eczema and psoriasis None Apply to the affected area as required or as in package insert
395 Colchicine 0.5mg Tablet M04AC01-000-T10-01-XXX B i) Acute gout and prophylaxis of recurrent gout.
ii) Leucocytoclastic Vasculitis either cutaneous or systemic involvement, Behcet's syndrome, Urticarial vasculitis, Systemic sclerosis, Sweet's syndrome and severe recalcitrant aphthous stomatitis		 None i) Acute gout:
Initial dose, 1 mg, then 0.5 mg after 1 hour. No further tablets should be taken for 12 hours. After 12 hours, treatment can resume if necessary with a maximum dose of 500 micrograms (1 tablet) every 8 hours until symptoms are relieved. The course of treatment should end when symptoms are relieved or when a total of 6 mg (12 tablets) has been taken. No more than 6 mg (12 tablets) should be taken as a course of treatment. After completion of a course, another course should not be started for at least 3 days (72 hours).
Prophylaxis of recurrent gout: 0.5 mg bd.

ii) 0.5 mg 1-3 times daily depends on disease and severity, up to a maximum of 3 mg/day
396 Colistimethate Sodium 1 million IU per vial (Polymyxin E) J01XB01-520-P40-01-XXX A* Intravenous administration for the treatment of serious infections caused by Gram negative bacteria, when more commonly used systemic antibacterial agents may be contraindicated or may be ineffective because of bacterial resistance. None A minimum of 5 days treatment is generally recommended. For the treatment of respiratory exacerbations in cystic fibrosis patients, treatment should be continued up to 12 days.

Children and adults (including elderly):
Up to 60kg: 50,000 units/kg/day to a maximum of 75,000 units/kg/day. The total daily dose should be divided into three doses given at approximately 8-hour intervals.
Over 60kg: 1-2 million units three times a day. The maximum dose is 6 million units in 24 hours.

Renal impairment:
In moderate to severe renal impairment, excretion of colistimethate sodium is delayed.
Dosage in Renal Impairment (for over 60 kg body weight):
- Mild (CrCl 20-50 ml/min): 1-2 million units every 8 hr.
- Moderate (CrCl 10-20 ml/min): 1 million units every 12-18 hr.
- Severe (CrCl <10 ml/min): 1 million units every 18-24 hr.
397 Colloidal Bismuth Subcitrate 120 mg Tablet A02BX05136T1001XX A Eradication therapy for Helicobacter Pylori in combination with antibiotics and antisecretory drugs 240 mg twice daily for 1-2 weeks
398 Compound Sodium Lactate (Hartmanns Solution) B05XA30125P6001XX C Replacement of extracellular losses of fluid and electrolytes, as an alkaliniser agent 100-1000 ml by IV or according to the needs of the patient
399 Conjugated estrogens 0.3 mg Tablet G03CA57-000-T10-03-XXX A i. Prevention and management of osteoporosis associated with estrogen deficiency.
ii. Female hypoestrogenism.
iii. Moderate to severe vasomotor symptoms associated with estrogen deficiency.
iv. Atrophic vaginitis and atrophic urethritis.		 None i) 0.3 - 0.625 mg daily
ii) 0.3- 1.25mg daily for 3weeks, then off for 1 week
iii) & iv) 0.3mg-1.25mg daily
400 Conjugated Estrogens 0.625 mg Tablet G03CA57-000-T10-01-XXX A i. Prevention and management of osteoporosis associated with estrogen deficiency.
ii. Female hypoestrogenism.
iii. Moderate to severe vasomotor symptoms associated with estrogen deficiency.
iv. Atrophic vaginitis and atrophic urethritis.		 None i) 0.3 - 0.625 mg daily
ii) 0.3- 1.25mg daily for 3weeks, then off for 1 week
iii) & iv) 0.3mg-1.25mg daily
401 Conjugated Estrogens 0.625mg/g Cream G03CA57-000-G10-01-XXX A Treatment of atrophic vaginitis, dyspareunia and kraurosis vulvae None i. Atrophic Vaginitis and Kraurosis Vulvae: Initial dose: Intravaginal 0.5g daily for 21 days and then off for 7 days (cyclical regimen). Dose range: 0.5- 2g daily based on individual response.

ii. Dyspareunia: 0.5g intravaginally twice weekly continuous regimen or in a cyclic regimen of 21 days of therapy followed by 7 days off of therapy.
402 Continuous Ambulatory Peritoneal Dialysis (CAPD) Solution containing 2.3% glucose (Calcium 1.75mmol/L) & (Calcium 1.25mmol/L) B05DB00908H2504XX B For chronic renal diseases requiring dialysis and acute therapy-resistance renal failure eg. prior to transfer to a dialysis centre Dose depending on clinical cases
403 Continuous Ambulatory Peritoneal Dialysis Solution containing 1.5% Dextrose B05DB00908H2501XX B For chronic renal diseases requiring dialysis and acute therapy-resistance renal failure eg. prior to transfer to a dialysis centre Dose depending on clinical cases
404 Continuous Ambulatory Peritoneal Dialysis Solution containing 2.5% Dextrose B05DB00908H2502XX B For chronic renal diseases requiring dialysis and acute therapy-resistance renal failure eg. prior to transfer to a dialysis centre Dose depending on clinical cases
405 Continuous Ambulatory Peritoneal Dialysis Solution containing 4.25% Dextrose B05DB00908H2503XX B For chronic renal diseases requiring dialysis and acute therapy-resistance renal failure eg. prior to transfer to a dialysis centre Dose depending on clinical cases
406 Copper 375mm2 Intrauterine Device G02BA02-000-M90-02-XXX B Intrauterine contraception. None Intrauterine insertion: 1 unit to be replaced within 5 years from the date of insertion.
407 Copper Sulphate Crystal D08A000183F9901XX C Wounds The tip of the crystal should be moistened by dipping in water and applied carefully to the lesion
408 Corifollitropin Alfa 100mcg/0.5ml solution for injection G03GA09-000-P50-01-XXX A* Controlled Ovarian Stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in woman participating in an Assisted Reproductive Technology (ART) program None Women with Body Weight ≤60 kg: A single dose of 100 mcg should be administered. Women with Body Weight >60 kg: A single dose of 150 mcg should be administered. Details : Refer to Product Information
409 Corifollitropin Alfa 150mcg/0.5ml solution for injection G03GA09-000-P50-02-XXX A* Controlled Ovarian Stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in woman participating in an Assisted Reproductive Technology (ART) program None Women with Body Weight ≤60 kg: A single dose of 100 mcg should be administered. Women with Body Weight >60 kg: A single dose of 150 mcg should be administered. Details : Refer to Product Information
410 Crotamiton 10 % Cream P03A000000G1001XX B i) Pruritus ii) Scabies iii) Insect bite reactions i) and iii) Massage into affected area until the medication is completely absorbed. Repeat as needed. Apply 2 or 3 times daily ii) Apply to the whole body from below the chin. 2nd application is applied 24 hr later. May need to use once daily for up to 5 days.
411 Cyanocobalamin 0.1 mg Injection B03BA01000P3001XX B i) Prophylaxis of anaemia ii) Uncomplicated pernicious anaemia or Vitamin B12 malabsorption i) Prophylaxis of anaemia: 250-1000 mcg IM every month ii) Uncomplicated pernicious anaemia or Vitamin B12 malabsorption: Initial 100 mcg daily for 5-10 days followed by 100-200 mcg monthly until complete remission is achieved. Maintenance: up to 1000 mcg monthly. CHILD 30-50 mcg daily for 2 or more weeks (to a total dose of 1-5mg). Maintenance: 100 mcg monthly to sustain remission OR AS PRESCRIBED.
412 Cyanocobalamin 1 mg Injection B03BA01000P3002XX B i) Prophylaxis of anaemia associated with Vitamin B12 deficiency ii) Uncomplicated pernicious anaemia or Vitamin B12 malabsorption i) Prophylaxis of anaemia: 250-1000 mcg IM every month ii) Uncomplicated pernicious anaemia or Vitamin B12 malabsorption: Initial 100 mcg daily for 5-10 days followed by 100-200 mcg monthly until complete remission is achieved. Maintenance: up to 1000 mcg monthly. CHILD 30-50 mcg daily for 2 or more weeks (to a total dose of 1-5mg). OR AS PRESCRIBED.
413 Cyanocobalamin 50 mcg Tablet B03BA01000T1002XX B Vitamin B12 deficiency of dietary origin ADULT 50-150 mcg daily. CHILD 50-105 mcg daily in 1-3 divided doses
414 Cyclopentolate 0.2% with Phenylephrine 1% Eye Drops S01GA55-990-D20-01-XXX A Dilating agent for premature babies None 1 drop every 5 - 10 minutes; not exceeding three times to produce rapid mydriasis. Observe infants closely for at least 30 minutes
415 Cyclopentolate 1% Eye Drops S01FA04-000-D20-02-XXX A/KK Mydriasis and cycloplegia None ADULT : 1 drop of solution in eye(s); may repeat after 5-10 minutes if needed. CHILD : 1 drop of solution in eye(s); may repeat after 5-10 minutes if needed. Pre-treatment on the day prior to examination is usually not necessary. If desirable, 1 or 2 drops may be instilled the evening prior to examination.
416 Cyclophosphamide 1 g Injection L01AA01000P4002XX A i) Solid tumours
ii) Leukaemia, non-Hodgkin's lymphoma, multiple myeloma
iii) Severe lupus nephritis (Class III and IV)
iv) Other systemic vasculitis
v) Systemic lupus erythematosus, rheumatoid arthritis, polyarteritis nodosa, wegener granulomatosis
vi) Pemphigus vulgaris.		 i) & ii) ADULT: 600 - 750 mg/m2 IV once every 3 weeks as part of combination regime. CHILD: Dose variable depending on disease and protocol. Range 600 mg/m2 to 2 g/m2 infusion over 1 hour to 6 hours (lower doses can be given as bolus). Care with pre and post-hydration. Mesna to be given with doses more than 1 g/m2. Higher doses are used in haematopoetic stem cell transplant-refer to specific protocols
iii) 750 mg/m2 BSA monthly for 18 months
iv) 750 mg/m2 BSA monthly for 6 months. Dose can be adjusted up to 1,000 mg/m2 BSA to achieve adequate leucocyte suppression
v) 500 - 1000 mg intravenously (Regime varies according to indication). Starting dose may be given fortnightly then at monthly intervals followed by 3 monthly intervals;
vi) 500 mg infusion on the 2nd day of the dexamethasone-cyclophosphamide pulsed regime, the cycle is repeated every 4 weeks up to 6 cycles or till remission followed by oral cyclophosphamide
417 Cyclophosphamide 200 mg Injection L01AA01000P4001XX A i) Solid tumours
ii) Leukaemia, non-Hodgkin's lymphoma, multiple myeloma
iii) Severe lupus nephritis (Class III and IV)
iv) Other systemic vasculitis
v) Systemic lupus erythematosus, rheumatoid arthritis, polyarteritis nodosa, wegener granulomatosis
vi) Pemphigus vulgaris.		 i)& ii) ADULT: 600 - 750 mg/m2 IV once every 3 weeks as part of combination regime. CHILD: Dose variable depending on disease and protocol. Range 600 mg/m2 to 2 g/m2 infusion over 1 hour to 6 hours (lower doses can be given as bolus). Care with pre and post-hydration. Mesna to be given with doses more than 1 g/m2. Higher doses are used in haematopoetic stem cell transplant-refer to specific protocols iii) 750 mg/m2 BSA monthly for 18 months iv) 750 mg/m2 BSA monthly for 6 months. Dose can be adjusted up to 1,000 mg/m2 BSA to achieve adequate leucocyte suppression v) 500 - 1000 mg intravenously (Regime varies according to indication). Starting dose may be given fortnightly then at monthly intervals followed by 3 monthly intervals; vi) 500 mg infusion on the 2nd day of the dexamethasone-cyclophosphamide pulsed regime, the cycle is repeated every 4 weeks up to 6 cycles or till remission followed by oral cyclophosphamide
418 Cyclophosphamide 50 mg Tablet L01AA01000T1001XX A i) Solid tumours, leukaemia, lymphoma, autoimmune disorders, autoimmune bullous diseases, connective tissue disease, pyoderma gangrenosum
ii) For severe lupus nephritis (Class III & IV), systemic vasculitis and steroid resistant/dependent nephrotic syndrome
iii) Systemic lupus erythematosus (SLE), rheumatoid arthritis, polyarteritis nodosa, wegener granulomatosis		 i) ADULT: 50 - 100 mg/day. Monitor full blood count (FBC), liver function, urine microscopy and renal function. CHILD, up to 1 year: 10 - 20 mg daily, 1 - 5 years: 30 - 50 mg daily, 6 - 12 years: 50 - 100 mg daily
ii) 2 mg/kg/day for 3 - 4 months
iii) 1 - 1.5 mg/kg/day orally in divided doses
419 Cycloserine 250mg Capsule J04AB01-000-C10-01-XXX A* Multi-Drug Resistance Tuberculosis treatment failure. (For respiratory physicians) None ADULT: Initial: 250 mg every 12 hours for 14 days, then administer 0.5 - 1 g daily in 2 divided doses for 18 - 24 months (maximum daily dose: 1 g). CHILD: 2-12 yr: 5 mg/kg bid; 12-18 yr: 250 mg bid for 2 wk then adjusted to a max dose of 1 g daily
420 Cyproterone Acetate 2 mg & Ethinyloestradiol 0.035 mg Tablet G03HB01-954-T10-01-XXX A* i. Treatment androgen dependent diseases (including PCOS) in women
ii.Treatment of acne as second line treatment following failure of topical therapy or systemic antibiotic treatment
iii.Hormonal contraceptive		 None 1 tablet daily for 21 consecutive days, followed by a 7 -day tablet free interval before the next pack is started

Halaman-halaman